TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor

Blood

Volumn 93, Issue 5, 1999, Pages 1707-1714

  Tomasson, Michael H ^b   Williams, Ifor R ^b   Hasserjian, Robert ^b   Udomsakdi, Chirayu ^b   McGrath, Shannon M ^b   Schwaller, Juerg ^b   Druker, Brian ^b   Gilliland, D Gary ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMATINIB; IMMUNOGLOBULIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING PROTEIN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENZYME INHIBITOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV6;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; GENE REARRANGEMENT; IMMUNOBLOTTING; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; ANIMAL; BLOOD DISEASE; DRUG ANTAGONISM; GENE TRANSLOCATION; GENETICS; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HEMATOLOGIC NEOPLASMS; MICE; MICE, TRANSGENIC; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 0033084227     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.5.1707     Document Type: Article

References (32)

1. Lichtman MA, Brennan JK: Dyshemopoietic (preleukemic) Disorders (ed 3). New York, NY, McGraw-Hill, 1983
2. De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, Meloni G, Mauri S, Carella A, Apperley J, Gratwohl A, Laporte J: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and acute leukemia working parties of the European Group for Blood and Marrow Transplantation. Blood 90:3853, 1997
3. Anderson J, Sale G, Appelbaum F, Chauncey T, Storb R: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677, 1993
4. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307, 1994
5. Berkowicz M, Rosner E, Rechavi C, Mamon Z, Neuman Y, Ben-Bassat I, Ramot B: Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12): A new assocation? Cancer Genet Cytogenet 51:277, 1991
6. Keene P, Mendelow B, Pinto MR, Bezwoda W, MacDougall L, Falkson G, Ruff P, Bernstein R: Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: A non-random association. Br J Haematol 67:25, 1987
7. Lerza R, Castello G, Sessarego M, Cavallini D, Pannacciulli I: Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12)(q33;p12-13). Br J Haematol 82:476, 1992
8. Srivastava A, Boswell H, Heerema NA, Nahreini P, Lauer RD, Antony AS, Hoffman R, Tricot GJ: KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. Cancer Genet Cytogenet 35:61, 1988
9. Wessels JW, Fibbe WE, van der Keur D, Landegent JE, van der Plas DC, den Ottolander GJ, Roozendaal KJ, Beverstock GD: t(5; 12)(q31;p12): A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia. Cancer Genet Cytogenet 65:7, 1993
10. Carroll M, Tomasson M, Barker GF, Golub TR, Gilliland DG: The TEL-PDGFβR fusion protein dimerizes and transforms hematopoietic cells through activation of PDGFβR dependent signaling pathways. Proc Natl Acad Sci USA 93:14845, 1996
11. Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J: A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFEβ oncoprotein. EMBO J 16:69, 1997
12. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
13. Schwaller J, Frantzve J, Tomasson M, McGrath SM, Ross TS, Aster J, Williams IR, Rompey LV, Marynen P, Van Etten R, Ilaria RJ, Gilliland DG: Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myeloid- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion gene. EMBO J 17:5321, 1998
14. Pear WP, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, Baltimore D: Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated notch alleles. J Exp Med 183:2283, 1996
15. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFβR fusion proteins. Blood 90:4947, 1997
16. Blankenstein T, Winter E, Müller W: A retroviral expression vector containing murine immunoglobulin heavy chain promoter/ enhancer. Nucleic Acids Res 16:10939, 1988
17. Speicher DW: Electrophoresis, in Coligan JE, Dunn BM, Ploegh HL, Speicher DW, Wingfield PT (eds): Current Protocols in Protein Science, Current Protocols. New York, NY, Wiley, 1995, p 10.1
18. Buffone GJ: Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 31:164, 1985
19. Davis RW: Rapid DNA isolations for enzymatic and hybridization analysis. Methods Enzymol 65:404, 1980
20. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
21. Kemp DJ, Harris AW, Cory S, Adams JM: Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines. Proc Natl Acad Sci USA 77:2876, 1980
22. Kemp DJ, Wilson A, Harris AW, Shortman K: The immunoglobulin mu constant region gene is expressed in mouse thymocytes. Nature 286:168, 1980
23. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K: Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 173:1213, 1991
24. Li Y-S, Hayakawa K, Hardy RR: The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med 178:951, 1993
25. Schmidt EV, Pattengale PK, Weir L, Leder P: Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: A pre-B-cell lymphoma model. Proc Natl Acad Sci USA 85:6047, 1988
26. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533, 1985
27. Condorelli G, Facchiano F, Valtieri M, Proietti E, Vitelli L, Lulli V, Huebner K, Peschle C, Croce C: T-cell direceted TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res 56:5113, 1996
28. Kelliher MA, Seldin DC, Leder P: Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J 15:5160, 1996
29. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker B, Lydon N: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100, 1996
30. Dedera DA, Wller EK, LeBrun DP, Sen-Majumdar A, Stevens ME, Barsh GS, Cleary ML: Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell 74:833, 1993
31. Druker B, Tamura S, Buchdunger E, Ohno S, Segal G, Fanning S, Zimmermann J, NB L: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561, 1996
32. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon N: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a novel tyrosine proein kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 92:2558, 1995